S-3304 | CAS#203640-27-1 | metalloproteinase inhibitor

MedKoo Cat#: 461641 | Name: S-3304

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

S-3304 is a sulfonamide derivative that acts as a matrix metalloproteinase inhibitor.

Chemical Structure

S-3304

CAS#203640-27-1

Theoretical Analysis

MedKoo Cat#: 461641

Name: S-3304

CAS#: 203640-27-1

Chemical Formula: C24H20N2O4S2

Exact Mass: 464.0864

Molecular Weight: 464.55

Elemental Analysis: C, 62.05; H, 4.34; N, 6.03; O, 13.78; S, 13.80

Price and Availability

Size	Price	Availability
1mg	USD 400.00	2 Weeks
5mg	USD 750.00	2 Weeks
10mg	USD 1,000.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

S-3304; S 3304; S3304;

IUPAC/Chemical Name

((5-(p-tolylethynyl)thiophen-2-yl)sulfonyl)-D-tryptophan

InChi Key

YWCLDDLVLSQGSZ-JOCHJYFZSA-N

InChi Code

InChI=1S/C24H20N2O4S2/c1-16-6-8-17(9-7-16)10-11-19-12-13-23(31-19)32(29,30)26-22(24(27)28)14-18-15-25-21-5-3-2-4-20(18)21/h2-9,12-13,15,22,25-26H,14H2,1H3,(H,27,28)/t22-/m1/s1

SMILES Code

O=C(O)[C@@H](CC1=CNC2=C1C=CC=C2)NS(=O)(C3=CC=C(C#CC4=CC=C(C)C=C4)S3)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

S-3304 is a MMP inhibitor specific for MMP-2 and MMP-9.

In vitro activity:

To be determined

In vivo activity:

S-3304 is safe, well tolerated, and achieves plasma concentrations above those required to inhibit MMP-2 and MMP-9. S-3304 prolongs survival in mice xenografts and is well tolerated in healthy volunteers. After S-3304 administration, 17 of 18 patients experienced inhibition of MMP activity by FIZ. Reference: Clin Cancer Res. 2007 Apr 1;13(7):2091-9. https://pubmed.ncbi.nlm.nih.gov/17404091/

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 464.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9. doi: 10.1158/1078-0432.CCR-06-1586. PMID: 17404091. 2. Mant TG, Bradford D, Amin DM, Pisupati J, Kambayashi Y, Yano Y, Tanaka K, Yamada-Sawada T. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. Br J Clin Pharmacol. 2007 May;63(5):512-26. doi: 10.1111/j.1365-2125.2006.02794.x. Epub 2006 Oct 31. PMID: 17076695; PMCID: PMC2000759.

In vitro protocol:

To be determined

In vivo protocol:

1: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):587-612. PMID: 15538546. 2: van Marle S, van Vliet A, Sollie F, Kambayashi Y, Yamada-Sawada T. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93. doi: 10.5414/cpp43282. PMID: 15968885. 3: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Oct;27(8):569-612. PMID: 16273137. 4: Mant TG, Bradford D, Amin DM, Pisupati J, Kambayashi Y, Yano Y, Tanaka K, Yamada-Sawada T. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. Br J Clin Pharmacol. 2007 May;63(5):512-26. doi: 10.1111/j.1365-2125.2006.02794.x. Epub 2006 Oct 31. PMID: 17076695; PMCID: PMC2000759. 5: Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada- Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9. doi: 10.1158/1078-0432.CCR-06-1586. PMID: 17404091. 6: Mortezapour M, Tapak L, Bahreini F, Najafi R, Afshar S. Identification of key genes in colorectal cancer diagnosis by co-expression analysis weighted gene co- expression network analysis. Comput Biol Med. 2023 May;157:106779. doi: 10.1016/j.compbiomed.2023.106779. Epub 2023 Mar 11. PMID: 36931200. 7: Mao G, Xu W, Wan L, Wang H, Xu S, Zhang L, Li S, Zhang J, Lai Z, Lan Y, Liu J. Unveiling the bioinformatic genes and their involved regulatory mechanisms in type 2 diabetes combined with osteoarthritis. Front Immunol. 2024 Aug 8;15:1353915. doi: 10.3389/fimmu.2024.1353915. PMID: 39176085; PMCID: PMC11338775.